Literature DB >> 19372795

The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure.

Janet D Siliciano1, Robert F Siliciano.   

Abstract

PURPOSE OF REVIEW: Despite remarkable progress in the development of drugs that inhibit HIV-1 replication, eradication of the infection has not been achieved. The principal reason is that the virus can persist in stable cellular reservoirs, the best characterized of which is a small pool of latently infected resting memory CD4 T cells that carry a stably integrated viral genome. This review covers recent discoveries on the biology of this reservoir, particularly as related to efforts to eliminate it. RECENT
FINDINGS: New studies suggest how the reservoir may be established during acute infection and define where the virus integrates in the human genome. In addition, the relationship between the latent reservoir and the residual low-level virus production that continues even in patients on optimal therapy is becoming clear. Several recent studies have described approaches for eliminating the latent reservoir. New insights into the biology of the reservoir are providing a context for understanding the enormous obstacles that must be overcome before the reservoir can be eliminated.
SUMMARY: The latent reservoir presents a formidable therapeutic challenge because it allows the virus to persist as genetic information in the form of a stably integrated provirus in an inherently stable cellular compartment. Eradication is complicated by the fact that the virus can undergo exponential expansion once drug pressure is released. Thus eradication must be complete to be effective.

Entities:  

Year:  2006        PMID: 19372795     DOI: 10.1097/01.COH.0000209582.82328.b8

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  20 in total

1.  Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells.

Authors:  Hao Yin; Yuhao Zhang; Xin Zhou; Huanzhang Zhu
Journal:  Mol Biol Rep       Date:  2010-12-23       Impact factor: 2.316

Review 2.  Potential implication of residual viremia in patients on effective antiretroviral therapy.

Authors:  Gautam K Sahu
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 3.  HIV Eradication Strategies: Implications for the Central Nervous System.

Authors:  Rebecca T Veenhuis; Janice E Clements; Lucio Gama
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

4.  HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection.

Authors:  Feng Yun Yue; Jared C Cohen; Mu Ho; A K M Nur-Ur Rahman; Jun Liu; Shariq Mujib; Aamir Saiyed; Sabrina Hundal; Alexandra Khozin; Phil Bonner; Daheng Liu; Erika Benko; Colin Kovacs; Mario Ostrowski
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

5.  Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Selwyn J Hurwitz; Raymond F Schinazi
Journal:  Drug Discov Today Technol       Date:  2012

6.  Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction.

Authors:  Adarsh M Kumar; Irina Borodowsky; Benny Fernandez; Louis Gonzalez; Mahendra Kumar
Journal:  J Neurovirol       Date:  2007-06       Impact factor: 2.643

7.  Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency.

Authors:  Haleh Rafati; Maribel Parra; Shweta Hakre; Yuri Moshkin; Eric Verdin; Tokameh Mahmoudi
Journal:  PLoS Biol       Date:  2011-11-29       Impact factor: 8.029

Review 8.  Bioinformatics and HIV latency.

Authors:  Angela Ciuffi; Pejman Mohammadi; Monica Golumbeanu; Julia di Iulio; Amalio Telenti
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

9.  Predictors of disease progression in HIV infection: a review.

Authors:  Simone E Langford; Jintanat Ananworanich; David A Cooper
Journal:  AIDS Res Ther       Date:  2007-05-14       Impact factor: 2.250

10.  Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.

Authors:  Elizabeth Hamlyn; Fiona M Ewings; Kholoud Porter; David A Cooper; Giuseppe Tambussi; Mauro Schechter; Court Pedersen; Jason F Okulicz; Myra McClure; Abdel Babiker; Jonathan Weber; Sarah Fidler
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.